A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 326 participants.
Also called NCT06344104
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 326 participants
- Sponsor
- Registry
-
NCT06344104
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Argentina, Australia, China, Hong Kong SAR China, India, Japan, Philippines, Russia, South Korea, Türkiye, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT06344104. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-08 (actual); primary completion 2025-11-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
- Acronym
- BaxAsia
- Condition
- Uncontrolled Hypertension
- Condition
- Resistant Hypertension
- Intervention (Drug)
- Baxdrostat
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06344104- Content hash
5a320150c9b79ca461a9804d5eea4fdbb43d65fc8432662d1ca9ec544181890d